This is the authors' abstract. We don't add key points for this paper.
As patient survival drops precipitously from early-stage cancers to late-stage and metastatic cancers, microRNAs that promote relapse and metastasis can serve as prognostic and predictive markers as well as therapeutic targets for chemoprevention. Here we show that miR-1269a promotes colorectal cancer (CRC) metastasis and forms a positive feedback loop with TGF-β signalling. miR-1269a is upregulated in late-stage CRCs, and long-term monitoring of 100 stage II CRC patients revealed that miR-1269a expression in their surgically removed primary tumours is strongly associated with risk of CRC relapse and metastasis. Consistent with clinical observations, miR-1269a significantly increases the ability of CRC cells to invade and metastasize in vivo. TGF-β activates miR-1269 via Sox4, while miR-1269a enhances TGF-β signalling by targeting Smad7 and HOXD10, hence forming a positive feedback loop. Our findings suggest that miR-1269a is a potential marker to inform adjuvant chemotherapy decisions for CRC patients and a potential therapeutic target to deter metastasis. Colorectal cancer (CRC), like many solid tumours, progresses from adenomas to carcinomas in a sequence that leads to metastasis. Here the authors show that miR1269 plays a role in CRC relapse and metastasis by regulating TGF-β activity.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bu et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: